Scott Dunseth Myers, President and CEO at Cascadian Therapeutics, Inc. (CASC), bought 5,500 shares at $3.74 ($21K) on 2017-08-11, disclosed to the SEC on 2017-08-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| VRDN | BUY | 2023-04-12 | $101K | — | Filing → |
| VRDN | BUY | 2023-03-13 | $160K | — | Filing → |
| CASC | BUY | 2017-05-16 | $11K | — | Filing → |